Innovation in Pediatric Drugs Act of 2025

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521/S. 4440: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. H.R. 8839: Lainie Jones Comprehensive Cancer Survivorship Act of 2026 to address the health of cancer survivors.

Client expense: $480,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer, HR 8839, The Lainie Jones Comprehensive Cancer Survivorship Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FY26 Labor, Health and Human Services, and Education Appropriations Bill: Pediatric Subspecialty Loan Repayment Program, Firearm Injury and Mortality Prevention Research, Pediatric Mental Health Care Access Program, Emergency Medical Services for Children, National Center for Birth Defects and Developmental Disabilities, Global Immunization, Vaccine Injury Compensation Program, Antimicrobial Resistance, Maternal and Child Health, Newborn Screening Saves Lives Reauthorization Act Strengthening the Vaccines for Children Program Act FY26 National Defense Authorization Act IDEA Full Funding Act (H.R.2598) PREEMIE Reauthorization Act (H.R. 1197) Preventing Maternal Deaths Reauthorization Act of 2025 (H.R.1909) Artificial Intelligence TRICARE Autism Maternal mental health/perinatal mental health Vaccines Lifespan Respite Care Reauthorization Act (S.830/H.R.2560) FASD Respect Act (S. 139) Family Vaccine Protection Act (H.R.3701) VACCINE Act HEADS UP Act (H.R.3409) Protecting Free Vaccines Act PREVENT HPV Cancers Act (H.R. 6561) Vaccine Transportation Access Act Innovation in Pediatric Drugs Act (S.705) & Policies to Strengthen Pediatric Research Equity Act Best Pharmaceuticals for Children Act Pediatric Research Equity Act Prescription Drug User Fee Amendments Pediatric Trials Network Artificial Intelligence Global Child Thrive Reauthorization Act Fiscal Year 2027 Appropriations bills (Labor HHS and SFOPS/NSRP) Protecting Sensitive Locations Act (H.R.5166 / S.455) Early Childhood Development programming Family Detention / DHS policies Unaccompanied Children's Program / Office of Refugee Resettlement PAHPA reauthorization Visas for International Medical Graduates Child passenger safety Appropriations for the Indian Health Service Appropriations for Environmental Programs (including EPA) Maternal, Infant, and Early Childhood Home Visiting Program & Implementation Infant sleep product safety Lead exposure prevention Food safety Paid family and medical leave Regulation of high-powered magnet sets Vehicle emissions standards Button battery ingestions Early childhood education (including Head Start, Childcare) Child product safety and injury prevention, including drowning prevention Child Abuse Prevention and Treatment Act (CAPTA) Family First Prevention Services Act implementation Title IV-B Congregate care reform Mental health supports for foster youth/former foster youth Mercury and Air Toxics Standards, ozone and particulate matter NAAQS, EPA greenhouse gas regulation, Endangerment Finding QRTP/IMDs Firearm Injury and Violence Prevention (Including Research Funding; Background Checks; Safe/Secure Storage) Childcare Funding & Resources Native American Child Health Water Beads Vaccines Fluoride Child Welfare & Medicaid, Social Services Block Grant (SSBG), Temporary Assistance for Needy Families (TANF), and Supplemental Nutrition Assistance Program (SNAP) Housing Prematurity Research Expansion and Education for Mothers who Deliver Infants Early (PREEMIE) Reauthorization Act Funding Newborn Screening Saves Lives Reauthorization Act (H.R. 4709) Donor Milk, Access to Donor Milk Act Title V Maternal and Child Health (MCH) Services Block Grant SSI Savings Penalty Elimination Act (S.1234/H.R.2590) Supplemental Security Income Equality Act (H.R. 2540) Autonomous Vehicles Pregnancy Risk Assessment Monitoring System (PRAMS) Data Collection Project Toxic Substances Control Act (TSCA) & Potential Changes Family Resource Centers Medicaid Payment Parity (including H.R. 1433 / S. 760 - Kids Access to Primary Care Act) Access to Care in Medicaid/CHIP Medicaid/CHIP federal funding Accelerating Kids Access to Care Act (H.R. 1509 / S. 752) H.R. 4641 - Keep Kids Covered Act S. 2287/H.R. 4425 - Palliative Care and Hospice Education and Training Act (PCHETA) Telehealth - Medicare telehealth extension, CONNECT for Health Act (S. 1261) One Big Beautiful Bill Act (H.R. 1) Hospital at Home Program Vaccines for Children Program Children and Teens Online Privacy Protection Act (H.R. 6291/S. 836) Kids Online Safety Act (H.R. 6484/S.1748) Artificial Intelligence and Child Health Legislation to Protect Young People Online Pediatric Specialty Loan Repayment Program Funding and Program Implementation EMPOWER for Health Act Tobacco Product Regulation/Enforcement Resources to Prevent Youth Vaping Act (S. 4257) Funding for Tobacco Control Programs Biomedical Research Funding (NIH, NICHD, AHRQ, etc.) LGBTQ Health Funding for Health Workforce Programs Funding for WIC SNAP/Farm Bill Mental Health for Children MODERN WIC Act/21st Century WIC Act Breastfeeding Peer Counseling Program Funding for HRSA Pediatric Mental Health Care Access Program Donor Milk Dietary Guidelines Suicide Prevention School Meal Standards WIC Food Packages Whole Milk Supporting Childrens Mental Health Care Access Nutrition Infant Formula Medicaid Immigration Child Welfare Vaccines Healthcare Workforce

Client expense: $320,000 · Firm income: Not reported

Government targets: Administration for Children & Families (ACF), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Indian Health Service, Interior, Dept of (DOI), Natl Institutes of Health (NIH), Office of the Comptroller of the Currency (OCC), SENATE, Social Security Administration (SSA), State, Dept of (DOS), U.S. Agency for International Development (USAID)

Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Use of provider-neutral and inclusive language in federal documents, forms, and surveys Reintroduction of the Primary and Behavioral Health Care Access Act Reauthorization of the Child Nutrition Act Implementation of 42 USC 300gg-5(a) regarding provider non-discrimination by health plans Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention Tobacco and vaping prevention and cessation Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) H.R. 1197/S. 1562, PREEMIE Reauthorization Act H.R. 1435/S. 3714, Family-to-Family Reauthorization Act of 2025 H.R. 1627, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 1834, Breaking the Gridlock Act H.R. 1909/S. 2621, Preventing Maternal Deaths Act H.R. 2223, Building Capacity for Care Act H.R. 3333, Magnifying Opportunities to Recruit and Educate (MORE) Nurses Act H.R. 3492, Protect Childrens Innocence Act H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4262/S. 4110, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4340/S. 921, Tyler's Law H.R. 4564, Dillons Law H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 H.R. 5469/S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 5629, To provide that the HHS final rule titled Medications for the Treatment of Opioid Use Disorder (except the portion relating to accreditation of opioid treatment programs) shall have no force or effect H.R. 6088/S. 3281, Restoring Food Security for Families & Farmers Act of 2025 H.R. 6252, Food Assurance and Security Act H.R. 6396, Kid Providing Resources for Optimal Outcomes against Fatalities (Kid PROOF) Act of 2025 H.R. 6561, PREVENT HPV Cancers Act of 2025 H.R. 6703, Lower Health Care Premiums for All Americans Act H.R. 6844, Tobacco TRACE Act H.R. 6845/S. 3569, S.T.O.P. Illegal Vaping Act H.R. 6945/S. 4242, Supporting Pregnant and Parenting Women and Families Act H.R. 7092, Raising Awareness for Youth Suicide (RAYS) Prevention Act H.R. 7567, Farm, Food, and National Security Act of 2026 H.R. 7757, Kids Internet and Digital Safety (KIDS) Act H.R. 7973, Momnibus Act H.R. 8089/S. 4186, Perinatal Workforce Act S. 222/H.R. 649, Whole Milk for Healthy Kids Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025 S. 1885, Stop the Scroll Act S. 1261, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 S. 1482, National Nursing Workforce Center Act of 2025 S. 1599/H.R. 6394, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748/H.R. 6484, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2169, Rural Hospital Cybersecurity Enhancement Act S. 2857/H.R. 5448, Protecting Free Vaccines Act S. 2954, Health Care Workforce Expansion Act of 2025 S. 3199, 988 Lifeline Location Improvement Act of 2025 S. 3315, Health Care Cybersecurity and Resiliency Act of 2025 S. 3386, Health Care Freedom for Patients Act of 2025 S. 3853, End the Vaccine Carveout Act S. 4088, Welcome Back to the Health Care Workforce Act S. 4189, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Biomedical Advanced Research and Development Authority (BARDA) ---Centers for Disease Control and Prevention ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---HHS Office of Infectious Disease and HIV/AIDS Policy ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---H.R.1262/S.932: Mikaela Naylon Give Kids A Chance Act ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Funding for Women's Health Research ---Implementation of the Inflation Reduction Act (IRA) ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---340B Rebate Rule ---Program Implementation & Oversight Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Disease X Act ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes ---White House National Biodefense Strategy ---WHO Pandemic Preparedness Accord Biosimilars ---Biosimilars Competition (General) ---Biosimilar Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution ---Purple Book Draft Legislation ---Reimbursement Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act Clinical Trial Data in China Data Privacy ---American Privacy Rights Act ---Clinical Trial Data in China ---Consumer Data Privacy and Security Act (Draft) ---Data Privacy Working Group Draft ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---Decentralized Clinical Trials Drug Evaluation and Review ---FDA Hiring Flexibility ---Promising Pathway Act ---PDUFA VII Implementation ---PDUFA VIII Negotiations Drug Importation Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability ---Contract Manufacturing Ecosystem in the United States Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act ---Ensuring Access to Generic Medications Act Drug Pricing ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.6166: Lowering Drug Costs for American Families Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1302: Increasing Transparency in Generic Drug Application ---Access to Innovative Treatments Act ---Biosimilar Red Tape Elimination Act ---CMMI: GLOBE and GUARD Models ---CMMI Authority ---DRUG Act ---Ensuring Access to Generic Medications Act ---Ensuring Timely Access to Generics ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Medicare Drug Price Negotiation Act ---Modernizing and Ensuring PBM Accountability (MEPA) Act ---National Coverage Determination ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---Tariffs Efforts to Expand the Bio Economy & Bio Manufacturing Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---S.1302: Increasing Transparency in Generic Drug Applications Act ---Generic Drug Application Review Reforms ---Incentives for Generic Entry Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act of 2025 ---Average Manufacturer Price Calculations ---CMMI (GENEROUS Model) ---CMMI: GLOBE and GUARD Models ---Drug Benefit Design ---International Pricing Policies ---Medicaid VBPs for Patients (MVP) Act ---Modernizing and Ensuring PBM Accountability (MEPA) Act ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates ---Alternative Payment Arrangements for Gene Therapies National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---National Defense Authorization Act of 2027 National Security ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance ---Most Favored Nation Drug Pricing Proposals Opioid Crisis ---Coverage and Reimbursement ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit ---Retaining Access and Restoring Exclusivity (RARE) Act ---Pediatric Priority Review Voucher Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Supply Chain Issues ---WHO Pandemic Preparedness Accord Precision Medicine Initiative Rare Pediatric Disease Priority Review ---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act ---Pediatric Priority Review Voucher ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.6166: Lowering Drug Costs for American Families Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---340B Rebate Rule ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicaid VBPs for Patients (MVP) Act ---Medicare Drug Price Negotiation Act ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---SAFE STEP Act ---Step Therapy ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications Vaccines and Infectious Diseases ---Adult Immunization ---Let Injured Americans Be Legally Empowered (LIABLE) Act ---Mandating Exclusive Review of Individual Treatments (MERIT) Act ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---National Coverage Determination ---PASTEUR ACT ---SAFE STEP Act ---Vaccine Access Improvement Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Modernization Act ---Vaccine Injury Compensation Program ---Vaccine Quality Measure ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence

Client expense: $1,620,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Mikaela Naylon Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses.

Client expense: $210,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FY26 Labor, Health and Human Services, and Education Appropriations Bill: - Pediatric Subspecialty Loan Repayment Program - Firearm Injury and Mortality Prevention Research - Pediatric Mental Health Care Access Program - Emergency Medical Services for Children - National Center for Birth Defects and Developmental Disabilities - Global Immunization - Vaccine Injury Compensation Program - Antimicrobial Resistance - Maternal and Child Health Newborn Screening Saves Lives Reauthorization Act Strengthening the Vaccines for Children Program Act FY26 National Defense Authorization Act IDEA Full Funding Act (H.R.2598) PREEMIE Reauthorization Act (H.R.1197) Preventing Maternal Deaths Reauthorization Act of 2025 (H.R.1909) Artificial Intelligence TRICARE Autism Maternal mental health/perinatal mental health Vaccines Lifespan Respite Care Reauthorization Act (S.830/H.R.2560) FASD Respect Act (S.139) Family Vaccine Protection Act (H.R.3701) VACCINE Act HEADS UP Act (H.R.3409) Protecting Free Vaccines Act PREVENT HPV Cancers Act (H.R.6561) Vaccine Transportation Access Act MDUFA VI Reauthorization Innovation in Pediatric Drugs Act (S.705) & Policies to Strengthen Pediatric Research Equity Act Best Pharmaceuticals for Children Act Pediatric Research Equity Act Prescription Drug User Fee Amendments Pediatric IBD Drug Development Health Information Privacy Reform Act (S.3097) Child passenger safety Appropriations for the Indian Health Service Appropriations for Environmental Programs (including EPA) Maternal, Infant, and Early Childhood Home Visiting Program & Implementation Infant sleep product safety Lead exposure prevention Food safety Paid family and medical leave Regulation of high-powered magnet sets Vehicle emissions standards Button battery ingestions Early childhood education (including Head Start, Childcare) Child product safety and injury prevention, including drowning prevention Child Abuse Prevention and Treatment Act (CAPTA) Family First Prevention Services Act implementation Title IV-B Congregate care reform Mental health supports for foster youth/former foster youth Mercury and Air Toxics Standards, ozone and particulate matter NAAQS, EPA greenhouse gas regulation, Endangerment Finding QRTP/IMDs Firearm Injury and Violence Prevention (Including Research Funding; Background Checks; Safe/Secure Storage) Childcare Funding & Resources Native American Child Health Water Beads Vaccines Fluoride Child Welfare & Medicaid, Social Services Block Grant (SSBG), Temporary Assistance for Needy Families (TANF), and Supplemental Nutrition Assistance Program (SNAP) Housing Prematurity Research Expansion and Education for Mothers who Deliver Infants Early (PREEMIE) Reauthorization Act of 2025 (S.1562/H.R.1197) Newborn Screening Saves Lives Reauthorization Act (H.R.4709) Donor Milk Title V Maternal and Child Health (MCH) Services Block Grant SSI Savings Penalty Elimination Act (S.1234/H.R.2590) Supplemental Security Income Equality Act (H.R.2540) Autonomous Vehicles Pregnancy Risk Assessment Monitoring System (PRAMS) Data Collection Project Toxic Substances Control Act (TSCA) & Potential Changes Medicaid Payment Parity (including H.R.1433 / S.760 - Kids Access to Primary Care Act) Access to Care in Medicaid/CHIP Medicaid/CHIP federal funding Accelerating Kids Access to Care Act (H.R.1509 / S.752) H.R.4641 - Keep Kids Covered Act S.2287/H.R.4425 - Palliative Care and Hospice Education and Training Act (PCHETA) Telehealth - Medicare telehealth extension, CONNECT for Health Act (S.1261) One Big Beautiful Bill Act (H.R.1) Proposed Rulemaking: Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children (CMS-2451-P) and Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children (CMS-3481-P) Children and Teens Online Privacy Protection Act (H.R.6291/S.836) Kids Online Safety Act (H.R.6484/S.1748) Artificial Intelligence and Child Health Legislation to Protect Young People Online Pediatric Specialty Loan Repayment Program Funding and Program Implementation EMPOWER for Health Act Regulation/Enforcement of Tobacco Products - Tobacco TRACE Act (H.R.6845) - STOP Illicit Vaping Act (H.R.6844/S.3569) Funding for Tobacco Control Programs Biomedical Research Funding (NIH, NICHD, AHRQ) LGBTQ Health Care Financing and Access - H.R.3492 - H.R.498 LGBTQ Health Care Financing and Access - Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children (CMS-3481-P) - Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children (CMS-2451-P) Global Child Thrive Reauthorization Act Notice of Proposed Rulemaking DHS Docket No. USCIS-2025-0304 The Department of State Reauthorization Act Protecting Sensitive Locations Act (H.R.5166 / S.455) Federal HIV Guidelines Family Detention / DHS policies Unaccompanied Children's Program / Office of Refugee Resettlement Child Nutrition Reauthorization/WIC SNAP/Farm Bill Mental Health for Children Medical Foods and Formulas Access Act WIC Act MODERN WIC Act Breastfeeding Peer Counseling Program Mental Health Services for Students Act of 2025 (H.R.5557) School Meals Expansion Funding for HRSA Pediatric Mental Health Care Access Program Funding for WIC Donor Milk Dietary Guidelines

Client expense: $100,000 · Firm income: Not reported

Government targets: Administration for Children & Families (ACF), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Indian Health Service, Interior, Dept of (DOI), Natl Institutes of Health (NIH), Office of the Comptroller of the Currency (OCC), SENATE, Social Security Administration (SSA), State, Dept of (DOS), U.S. Agency for International Development (USAID)

Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) Reintroduction of the Nurse Faculty Shortage Reduction Act H.R. 498, Do No Harm in Medicaid Act H.R. 1197/S. 1562, PREEMIE Reauthorization Act H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 1909/S. 2621, Preventing Maternal Deaths Act H.R. 2223, Building Capacity for Care Act H.R. 2483/S. 2121, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 3492, Protect Childrens Innocence Act H.R. 3684, Save Americas Rural Hospitals Act of 2025 H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4231/S. 1973, Treat and Reduce Obesity Act H.R. 4262, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 H.R. 6561, Prevent HPV Cancers Act of 2025 H.R. 6703, Lower Health Care Premiums for All Americans Act S. 222, Whole Milk for Healthy Kids Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act S. 891, Bipartisan Health Care Act S. 1261, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 S. 1482, National Nursing Workforce Center Act of 2025 S. 1599, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748/H.R. 6484, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2857/H.R. 5448, Protecting Free Vaccines Act S. 2954, Health Care Workforce Expansion Act of 2025 S. 3435/H.R. 6607, Future Advancement of Academic Nursing (FAAN) Act S.J. Res. 82, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Office of the Secretary of the Department of Health and Human Services relating to Policy on Adhering to the Text of the Administrative Procedure Act

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

FY 2026 Appropriations for Agencies ---ASPR ---Centers for Disease Control and Prevention ---FDA ---Health Resources and Services Administration (HRSA) ---HHS Office of Infectious Disease and HIV/AIDS Policy ---National Institutes of Health FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---Creating Hope Reauthorization Act ---Drug Pricing ---Funding for Strategic National Stockpile ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---PPRV ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of PAHPA ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.6166: Lowering Drug Costs for American Families Act ---340B Accountability Act ---Executive Order on Access to Affordable Life-Saving Medications ---Program Implementation & Oversight ---PROTECT 340B Act ---SUSTAIN 340B Act Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---BIOSECURE Act ---House GOP RFI on Supply Chain ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2026 ---Reasonable Pricing Clauses in BARDA Contracts ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---State Strategic Stockpile Act ---Synthetic Nucleic Acid Synthesis Screening ---VICP Loopholes ---WHO Pandemic Preparedness Accord Biosimilars ---Biosimilar Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution ---Preserve Access to Affordable Generics and Biosimilars Act ---Reimbursement Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act Clinical Trial Data in China Data Privacy ---BIOSECURE Act ---Clinical Trial Data in China Drug Evaluation and Review ---FDA Hiring Flexibility ---PDUFA VIII Negotiations ---Promising Pathway Act Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Compounding Pharmacies ---Contract Manufacturing Ecosystem in the United States ---Drug Shortages ---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy ---Supply Chain Integrity and Traceability Drug Patenting ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act ---A bill to address patent thickets ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.6166: Lowering Drug Costs for American Families Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1302: Increasing Transparency in Generic Drug Application ---Access to Innovative Treatments Act ---Biologics Competition Act ---Biosimilar Red Tape Elimination Act ---CMMI Authority ---COVID-19 Pricing-Related Provisions ---DRUG Act ---Ensuring Access to Generic Medications Act ---Ensuring Timely Access to Generics ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Mandating Exclusive Review of Individual Treatments (MERIT) Act ---Medicare Drug Price Negotiation Act ---Medicare Negotiation and Competitive Licensing Act ---Modernizing and Ensuring PBM Accountability (MEPA) Act ---Most Favored Nation Drug Pricing Proposals ---National Coverage Determination ---Patient Cost-Sharing and Implementation ---Strengthening Innovation in Medicare and Medicaid Act Efforts to expand the Bio Economy & Bio Manufacturing Foreign Drug Data Protection Laws ---BIOSECURE Act Generic Drug Entry ---Enhanced Access to Affordable Medicines Act ---Generic Drug Application Review Reforms ---Incentives for Generic Entry Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act of 2025 ---Alternative Payment Arrangements for Gene Therapies ---Coverage of Accelerated Approval Products ---Drug Benefit Design ---Medicaid Drug Rebate Program Rule ---The Medicaid VBPs for Patients (MVP) Act ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule National Defense ---National Defense Authorization Act of 2026 National Security ---BIOSECURE Act ---Clinical Trial Data in China ---Most Favored Nation Pricing Opioid Crisis ---SUPPORT Act Orphan Drug Issues ---H.R.946/S.1862: ORPHAN Cures Act ---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit ---Retaining Access and Restoring Exclusivity (RARE) Act Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Supply Chain Issues ---Temporarily Refundable R&D Credit ---WHO Pandemic Preparedness Accord Precision Medicine Initiative Rare Pediatric Disease Priority Review ---H.R.1262/S.932 Mikaela Naylon Give Kids a Chance Act Reimbursement and Coverage of Innovative Products ---H.R.6166: Lowering Drug Costs for American Families Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---Administrative Rebate Rule ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Lower Costs, More Transparency Act ---Mandating Exclusive Review of Individual Treatments (MERIT) Act ---Medicare Drug Price Negotiation Act ---Medicare Part B Physician-Administered Products ---Patient Cost-Sharing and Smoothing ---Prescription Drug Price Relief Act ---Protected Classes ---SAFE STEP Act ---Step Therapy ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---Access to Innovative Treatments Act ---Adult Immunization ---Let Injured Americans Be Legally Empowered (LIABLE) Act ---Mandating Exclusive Review of Individual Treatments (MERIT) Act ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Monoclonal Antibody Coverage and Utilization ---National Coverage Determination ---PASTEUR ACT ---SAFE STEP Act ---Vaccine Access Improvement Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Modernization Act ---Vaccine Injury Compensation Program ---Vaccine Quality Measure ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence

Client expense: $1,510,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, SENATE, White House Office

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act

Client expense: $180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b) program.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention Reintroduction of the Future Advancement of Academic Nursing (FAAN) Act Reintroduction of the Prevent HPV Cancers Act Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) H.R. 290, Rural Telehealth and Education Enhancement Act H.R. 1197/S. 1562, PREEMIE Reauthorization Act H.R. 1715/S. 786, Public Health Funding Restoration Act H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 1909/S. 2621, Preventing Maternal Deaths Act H.R. 2223, Building Capacity for Care Act H.R. 2483/S. 2121, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 3505, Barriers to Suicide Act of 2025 H.R. 3684, Save Americas Rural Hospitals Act of 2025 H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4231/S. 1973, Treat and Reduce Obesity Act H.R. 4262, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836, Children and Teens Online Privacy Protection Act S. 891, Bipartisan Health Care Act S. 1261, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 S. 1482, National Nursing Workforce Center Act of 2025 S. 1599, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2355, Patients Deserve Price Tags Act S. 2954, Health Care Workforce Expansion Act of 2025

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act

Client expense: $180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 864: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4191: To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. Cures 2.1

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention Introduction of the Future Advancement of Academic Nursing (FAAN) Act H.R. 1, One Big, Beautiful Bill Act H.R. 27/S. 331, Halt All Lethal Trafficking of (HALT) Fentanyl Act H.R. 1715/S. 786, Public Health Funding Restoration Act H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 2223, Building Capacity for Care Act H.R. 2483/S. 2121, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 3701, Family Vaccine Protection Act S. Res. 206/H. Res. 389, Supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836, Children and Teens Online Privacy Protection Act S. 891, Bipartisan Health Care Act S. 931/H.R. 2509, Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act S. 1062, Suicide Prevention Act S. 1261, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 S. 1482, National Nursing Workforce Center Act of 2025 S. 1748, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 864: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4191: To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. Cures 2.1

Client expense: $650,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues Clinical trial policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program Issues related to the 340B Program. Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Patent use codes policy issue Pharmacy Benefit Manager reform and policy issues Rebate policy issues S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. The Orphans Cures Act" User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Vaccine provisions of the Inflation Reduction Act

Client expense: $800,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: Introduction of legislation to reauthorize nursing workforce development programs under Title VIII of the Public Health Service Act Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Health information technology and electronic health records Mental health services and violence prevention Introduction of the Womens and Family Protection Act H.R. 27/S. 331, Halt All Lethal Trafficking of (HALT) Fentanyl Act H.R. 1715/S. 786, Public Health Funding Restoration Act H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 2223, Building Capacity for Care Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 891, Bipartisan Health Care Act S. 1261, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues Clinical trial policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program Issues related to the 340B Program. Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Patent use codes policy issue Pharmacy Benefit Manager reform and policy issues Rebate policy issues S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. The Orphans Cures Act" User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Vaccine provisions of the Inflation Reduction Act

Client expense: $800,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

S. 652: Protecting Patients from Deceptive Drug Ads Act S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues

Client expense: $12,880,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Client expense: Not reported · Firm income: $420,000

340B Drug Discount Program ---340B Accountability Act ---Executive Order on Access to Affordable Life-Saving Medications ---Program Implementation & Oversight Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biosimilars ---Biosimilar Copay ---BSUFA Negotiations ---Implementation of BSUFA Agreement ---Interchangeability and Pharmacy Substitution ---Reimbursement ---General Cell & Gene Therapy ---H.R.1672 MINI Act Climate Change ---FY 2025 Appropriations ---FY 2026 Appropriations Clinical Trial Data in China Data Privacy ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Data Privacy ---General Diversity & Inclusion ---Decentralized Clinical Trials ---Clinical Trial Diversity ---General Drug Evaluation and Review ---Promising Pathway Act ---COVID-19 Lessons Learned ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Drug Shortages ---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy ---Supply Chain Integrity and Traceability ---Compounded Medicines Drug Patenting ---Interagency Patent Coordination and Improvement Act of 2025 ---Prescription Pricing for the People Act of 2025 ---Preserve Access to Affordable Generics and Biosimilars Act ---Stop STALLING Act ---Patent Thickets ---Restrictions on Intellectual Property Rights Drug Pricing ---FY2025 Appropriations ---FY 2026 Appropriations ---S.1097: Interagency Patent Coordination and Improvement Act of 2025 ---H.R.946: ORPHAN Cures Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---PBN Reform ---H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act ---S.526: Prescription Pricing for the People Act of 2025 ---S.527: Pharmacy Benefit Manager Transparency Act of 2025 ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1095: Stop STALLING Act ---CMMI Authority ---COVID-19 Pricing Related Provisions ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Patient Cost-Sharing and Implementation ---Strengthening Innovation in Medicare and Medicaid Act ---International Reference Pricing Foreign Drug Data Protection Laws ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Supply Chain ---Regulatory Harmonization Funding for Antimicrobial Resistance (AMR) Programs ---FY 2025 Appropriations ---FY 2026 Appropriations International Reference Pricing Issues Relating to Medical Research and Animal Testing Models Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act of 2025 ---Alternative Payment Arrangements for Gene Therapies ---Average Manufacturer Price Calculations ---Coverage of Accelerated Approval Products ---Drug Benefit Design ---Encouraging Innovation Benefit Design to Lower Costs for Seniors Act ---Medicaid Drug Rebate Program ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule National Defense ---National Defense Authorization Act of 2025 Opioid Crisis ---SUPPORT Act ---Non-Opioid Analgesics ---Transparency ---Coverage and Reimbursement Orphan Drug Issues ---H.R.946: ORPHAN Cures Act ---H.R.1262: Give Kids A Chance Act ---S.705: Innovation and Pediatric Drugs Act of 2025 ---Pediatric Priority Review Voucher Program Reauthorization ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit ---General Precision Medicine Initiative Reimbursement and Coverage of Innovative Products ---S.864: HELP Copays Act ---Administration Rebate Rule ---CMMI Authority ---In-Home Administration of Part B Drugs ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-based Contracting and Communications Vaccines and Infectious Diseases ---FY 2025 Appropriations ---FY 2026 Appropriations ---Adult Immunization ---Countermeasures Injury Compensation Program ---Vaccine Injury Compensation Program ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM PRV Reauthorization ---Monoclonal Antibody Coverage and Utilization ---National Coverage Determination ---Vaccine Safety and Quality ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence ---VICP Loopholes

Client expense: $890,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 1197, The PREEMIE Reauthorization Act of 2025 Issues related to H.R. 1909, Preventing Maternal Deaths Reauthorization Act of 2025 Issues related to 340B Issues related to pediatric health workforce & research legislation H.R. 1735 & S. 779 EARLY Minds Act S.1261, CONNECT for Health Act of 2025 S.705, Innovation in Pediatrics Drug Act H.R. 2002, Patient Matching and Transparency in Certified Health IT (MATCH IT) Act of 2025 Issues related to S. 721, Sickle Cell Disease Comprehensive Care Act Issues related to H.R.1796, S. 735, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Client expense: $247,496 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1261: CONNECT for Health Act- expands access to telehealth services under Medicare Medicare Physician Payment reforms: H. 879 - Medicare Patient Access and Practice Stabilization Act - Providing automatic inflationary updates to Medicare physician payments. Eliminate budget neutrality requirements. Meaningful changes to the Merit-Based Incentive Payment System (MIPS). Incentivizing the transition to value-based care including H.R. 786 - Preserving Patient Access to Accountable Care Act. Prior authorization reforms including H. 2433 - Reducing Medically Unnecessary Delays in Care Act and reintroduction of the Improving Seniors Timely Access to Care act. H.R. 1509/S. 752: Accelerating Kids Access to Care Act - To amend titles XIX and XXI of the Social Security Act to streamline the enrollment process for eligible out-of-state providers under Medicaid and CHIP. S. 705 - Innovation in Pediatric Drugs Act - to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations. Preserving the Medicaid Program for cancer patients.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE